What is the latest KIMS stock price?
The latest stored price for KIMS is Rs 782.50 as of 2026-08-21.
gimli
KIMS stock AI analysis
KIMS Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
KRISHNA INST OF MED SCI L is a small-cap stock in Healthcare. This Gimli page shows the latest available KIMS price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹782.50
1W return
-3.29%
1M return
-1.01%
3M return
+1.74%
6M return
+13.00%
1Y return
+4.87%
Market cap
₹31,310.87 cr
PE
153.26
PB
12.24
ROE
+8.21%
ROCE
+8.99%
RSI
40.86
Turnover
₹23.67 cr
Why it can matter in screens
- Momentum: KIMS is below 50DMA, above 200DMA; RSI is 40.86.
- Returns: 1D -0.95%, 1W -3.29%, 1M -1.01%, 3M +1.74%, 1Y +4.87%.
- Trend levels: 52W high ₹858.00, 52W low ₹725.40, off high -8.80%.
- Liquidity: latest turnover is ₹23.67 cr; volume vs 20D is +0.50%.
- Valuation/profitability: PE 153.26, PB 12.24, ROE +8.21%, ROCE +8.99%.
- Growth: 3Y sales CAGR +21.67%, 3Y profit CAGR -10.46%.
Quick Answers
Is KIMS above its 50DMA and 200DMA?
KIMS is below 50DMA, above 200DMA. The latest 50DMA is 803.31 and the latest 200DMA is 709.33.
What are KIMS PE, ROE and ROCE?
KIMS has PE 153.26, ROE +8.21%, and ROCE +8.99% in Gimli's latest available snapshot.
How has KIMS performed recently?
KIMS has returned -1.01% over 1 month, +1.74% over 3 months, and +4.87% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 1,179.50 cr | 240.80 cr | 41.50 cr | 1.04 |
| 2026-03-31 | 1,074.60 cr | 207.90 cr | 42.50 cr | 1.06 |
| 2025-12-31 | 997.70 cr | 204.10 cr | 53.40 cr | 1.33 |
| 2025-09-30 | 960.70 cr | 207.90 cr | 66.90 cr | 1.67 |
| 2025-06-30 | 871.60 cr | 199.70 cr | 78.60 cr | 1.96 |
| 2025-03-31 | 796.90 cr | 213.30 cr | 101.80 cr | 2.54 |
| 2024-12-31 | 772.40 cr | 205.00 cr | 88.70 cr | 2.22 |
| 2024-09-30 | 777.30 cr | 223.10 cr | n/a | 2.68 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 3,904.60 cr | 819.60 cr | 241.40 cr | 6.52 |
| 2025-03-31 | 3,035.00 cr | 825.60 cr | 384.50 cr | 9.61 |
| 2024-03-31 | 2,474.00 cr | 652.40 cr | 310.00 cr | 7.75 |
| 2023-03-31 | 2,167.66 cr | 643.49 cr | 336.32 cr | 8.41 |
| 2022-03-31 | 1,167.55 cr | 545.56 cr | 278.37 cr | 8.38 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 7,758.70 cr | 55.40 cr | 4,252.90 cr | 2,558.50 cr |
| 2025-03-31 | 5,736.00 cr | 56.00 cr | 2,556.70 cr | 2,418.80 cr |
| 2024-03-31 | 3,851.70 cr | 46.90 cr | 1,355.50 cr | 2,093.10 cr |
| 2023-03-31 | 2,941.30 cr | 61.61 cr | 678.17 cr | 1,937.96 cr |
| 2022-03-31 | 1,907.35 cr | 25.63 cr | 256.53 cr | 1,410.64 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 510.80 cr | -917.10 cr | n/a |
| 2025-03-31 | 581.80 cr | -427.10 cr | n/a |
| 2024-03-31 | 521.20 cr | -126.10 cr | n/a |
| 2023-03-31 | 432.09 cr | -142.44 cr | n/a |
| 2022-03-31 | 324.02 cr | 153.70 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +32.50% | +14.74% | +34.43% | +28.52% | +18.33% | +10.26% |
| 2026-03-31 | +34.11% | +14.57% | +32.50% | +27.41% | +18.82% | +10.26% |
| 2025-12-31 | +34.11% | +14.33% | +32.71% | +27.50% | +18.85% | +3.66% |
| 2025-09-30 | +34.11% | +15.03% | +32.12% | +26.72% | +18.74% | +0.00% |
| 2025-06-30 | +34.11% | +15.54% | +31.66% | +25.25% | +18.69% | +0.00% |
| 2025-03-31 | +38.82% | +15.45% | +31.95% | +25.35% | +13.78% | +12.03% |
| 2024-12-31 | +38.82% | +15.68% | +32.05% | +25.99% | +13.45% | +12.13% |
| 2024-09-30 | +38.82% | +15.85% | +32.30% | +25.77% | +13.03% | +15.35% |
| 2024-06-30 | +38.82% | +17.84% | +32.12% | +25.30% | +11.22% | +15.78% |
| 2024-03-31 | +38.82% | +16.73% | +33.13% | +26.33% | +11.32% | +16.10% |
| 2023-12-31 | +38.82% | +15.27% | +34.23% | +27.36% | +11.68% | +16.10% |
| 2023-09-30 | +38.84% | +14.25% | +34.80% | +27.01% | +12.11% | +16.16% |
| 2023-06-30 | +38.84% | +13.15% | +35.77% | +27.40% | +12.24% | +15.53% |
| 2023-03-31 | +38.84% | +19.40% | +29.76% | +21.68% | +12.00% | +18.10% |
| 2022-12-31 | +38.84% | +20.49% | +28.32% | +20.40% | +12.35% | +19.39% |
| 2022-09-30 | +38.84% | +20.59% | +27.98% | +20.49% | +12.59% | +19.39% |
| 2022-06-30 | +38.84% | +0.00% | +31.14% | n/a | n/a | +15.74% |
| 2022-03-31 | +38.84% | +0.00% | +29.93% | n/a | n/a | +14.86% |
| 2021-12-31 | +38.84% | +0.00% | +29.31% | n/a | n/a | +13.45% |
| 2021-09-30 | +38.84% | +0.00% | +28.54% | n/a | n/a | +13.45% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze KRISHNA INST OF MED SCI L with valuation, momentum and industry peers
- Compare KIMS with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare KIMS with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.